Latest Merger & Acquisition Life Science News

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

December 6
Last Trade: 149.28 1.31 0.89

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00 per share...Read more

R1 RCM to Acquire Acclara

December 6
Last Trade: 10.46 0.06 0.58

Acquisition of Providence’s Current Modular Services Business Accompanied by 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services R1 to Host Conference Call Today at 8:00 AM ET MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today...Read more

NEXGEL Acquires Kenkoderm Psoriasis Skincare Line

December 5
Last Trade: 2.16 0.13 6.42

Acquisition expands NEXGEL’s health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins Kenkoderm for the trailing twelve months is profitable and expected to be immediately accretive to NEXGEL LANGHORNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle,...Read more

Roche enters into definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

December 4
Last Trade: 36.00 0.42 1.18

Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche’s in-house assets Lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbidities Under the terms of the agreement, Roche will pay a purchase price of USD 2.7...Read more

HEALWELL AI Completes Acquisition of ‘Pentavere’, a Leading Healthcare AI and Data Science Company

HEALWELL completes acquisition of a majority stake of Pentavere, a healthcare artificial intelligence (AI) company who has built a best-in-class AI engine to help solve some of healthcare’s toughest data challenges. Pentavere has developed and validated leading capabilities in data structuring and abstraction; a key capability to unlocking clinical value and unmet needs for patients and providers. The Pentavere acquisition adds...Read more

Eli Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023

December 4
Last Trade: 598.05 9.78 1.66

INDIANAPOLIS, Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at...Read more

Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval

December 4
Last Trade: 1.24 0.05 4.20

BELLEVUE, Wash. / Dec 04, 2023 / Business Wire / Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the United States District Court for the Central District of California has approved the Purchase and Sale Agreement (“PSA”) which provides for the Company to acquire a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection,”...Read more

Nevro Announces Acquisition of Vyrsa™ Technologies

November 30
Last Trade: 19.95 0.46 2.36

Refinances with $200M Structured Debt Maturing in 2029 REDWOOD CITY, Calif., Nov. 30, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies ("Vyrsa"), a privately held medical technology company focused on a minimally invasive treatment option for patients...Read more

Johnson & Johnson MedTech Acquires Laminar

November 30
Last Trade: 154.42 -0.98 -0.63

Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating...Read more

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

November 30
Last Trade: 149.28 1.31 0.89

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has...Read more

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

November 28
Last Trade: 0.17 0.01 6.25

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and...Read more

Syncona to Acquire Freeline Therapeutics

November 22
Last Trade: 6.33 0.00 0.00

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to...Read more

Merck to Acquire Caraway Therapeutics

November 21
Last Trade: 103.75 -0.13 -0.13

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases RAHWAY, N.J., & CAMBRIDGE, Mass. / Nov 21, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a...Read more

American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

November 20
Last Trade: 2.52 0.08 3.28

Accretive Transaction to Expand U.S. Footprint  SAN FRANCISCO, CA, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ​​via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (“ASHS” or the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that it has entered into an Investment Purchase Agreement...Read more

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

November 20
Last Trade: 5.08 -0.06 -1.17

Acquisition includes OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra into commercial stage, diversifying its revenue and providing scale Settlement of Acer’s warrant obligations through direct transaction with a healthcare focused investment fund adds quality healthcare investor to Zevra’s shareholder base CELEBRATION, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc....Read more

Labcorp and Legacy Health Finalize Comprehensive Laboratory Relationship

November 20
Last Trade: 216.60 -1.03 -0.47

Agreement Expands Access to Labcorp's Diagnostics Capabilities and Services BURLINGTON, N.C., Nov. 20, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy's outreach laboratory business. Labcorp also now manages Legacy's inpatient hospital...Read more

Boston Scientific Closes Acquisition of Relievant Medsystems

November 17
Last Trade: 54.95 -0.08 -0.15

Recent healthcare plan coverage of Intracept® system expands access to vertebrogenic pain treatment for tens of millions of patients MARLBOROUGH, Mass., Nov. 17, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a...Read more

Q32 Bio and Homology Medicines Announce Merger Agreement

November 16
Last Trade: 0.56 -0.02 -3.17

The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and...Read more

Inari Medical Closes Acquisition of LimFlow

November 15
Last Trade: 63.05 -0.26 -0.41

IRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). “The close of the LimFlow acquisition allows us to...Read more

HEALWELL AI to Acquire Control of AI Leader ‘Pentavere’ to Help Solve Some of Healthcare’s Toughest Data Challenges

HEALWELL enters into agreement to acquire a majority stake of Pentavere, a healthcare artificial intelligence (AI) company whose DARWEN™ AI technology has been validated by some of the largest pharmaceutical companies in the world and whose research and validation has been published by some of the most prestigious publications globally. Pentavere has developed and validated best in class capabilities in data structuring and...Read more

Justera Health Completes Acquisition of K-Beauty Company, Triniti Trading

November 15
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") is pleased to announce it has completed the previously announced (see Press Release November 7, 2023) acquisition of all of the shares of Triniti Trading Corp. an authorized distributor of TonyMoly products in Canada (o/a TonyMoly Canada), a highly renowned beauty and skincare brand, on November 14,...Read more

LENZ Therapeutics and Graphite Bio Announce Merger Agreement

November 15
Last Trade: 2.25 -0.02 -0.88

Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET SAN DIEGO & SOUTH SAN FRANCISCO, Calif. /...Read more

Selecta Biosciences Announces Merger with Cartesian Therapeutics

November 13
Last Trade: 0.88 0.00 0.00

 Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease  Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG)  Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and...Read more

Neighbourly Pharmacy Extends Exclusivity and Provides Update on Letter of Intent with Persistence Capital Partners

November 13
Last Trade: 17.85 -0.01 -0.06

Committed Debt Financing Secured; Exclusivity Extended to January 15, 2024 TORONTO, Nov. 13, 2023 /CNW/ - Neighbourly Pharmacy Inc. ("Neighbourly" or the "Company") (TSX: NBLY), Canada's largest and fastest growing network of independent pharmacies, provides an update regarding the previously announced letter of intent entered into with an affiliate of Persistence Capital Partners (collectively, and together with their affiliated...Read more

Revolution Medicines Completes Acquisition of EQRx

November 9
Last Trade: 24.59 0.11 0.45

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted...Read more

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

November 8
Last Trade: 24.59 0.11 0.45

REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective special meetings, Revolution Medicines and EQRx stockholders voted to approve Revolution Medicines’ proposed acquisition of EQRx. The final votes will...Read more

Apollo Medical Announces Definitive Agreement to Acquire Assets of Community Family Care Medical Group IPA, Inc. and Health Plan

November 7
Last Trade: 33.38 0.10 0.30

ALHAMBRA, Calif., Nov. 7, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it and its affiliated professional entity have entered into a definitive agreement to...Read more

Justera Health Signs Definitive Agreement to Acquire K-Beauty Company, Triniti Trading

November 7
Last Trade: 0.02 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") is pleased to announce it has taken a significant step towards expanding its portfolio by signing a definitive agreement to acquire all of the shares of Triniti Trading Corp. an authorized distributor of TonyMoly in Canada (o/a TonyMoly Canada (the "Vendor")), a highly renowned beauty and skincare brand,...Read more

Health Catalyst Acquires ERS, Bolsters Tech-Enabled Managed Services Offering with Data Abstraction and Oncology Registry Management Capabilities

November 2
Last Trade: 7.76 0.06 0.78

SALT LAKE CITY, Nov. 2, 2023 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has acquired Electronic Registry Systems, Inc. (ERS), a market leader in cancer registry software and services. Headquartered in Cincinnati, Ohio, ERS provides cancer registry compliance and informatics services to enable...Read more

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

November 2
Last Trade: 0.25 0.00 0.00

CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the “Proposed Transaction”). This latest announcement is part of the Company’s new business strategy focusing on oncology. The Company plans to commercialize therapeutics, diagnostics...Read more

Pennant Acquires Northern Texas and Southern Oklahoma Hospice Provider

November 1
Last Trade: 13.54 0.23 1.73

EAGLE, Idaho, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced that it has acquired Guardian Hospice and Guardian Hospice of Oklahoma (“Guardian”), which provides skilled hospice services in Grayson, Fannin, Collin, Cook, Denton, and Hunt counties in Texas, and Bryan, Choctaw, Atoka,...Read more

Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow

November 1
Last Trade: 63.05 -0.26 -0.41

Announces Q3 2023 Financial Results Inari to Host Conference Call Today at 1:30 P.M PT / 4:30 P.M. ET IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it has entered into a definitive agreement to acquire LimFlow, S.A., a privately held...Read more

Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink

October 31
Last Trade: 489.77 -4.33 -0.88

Shareholders to Receive $26.00 per Common Share and ADS in Cash WALTHAM, Mass. & UPPSALA, Sweden / Oct 31, 2023 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that Thermo Fisher has commenced the previously announced tender offer (the...Read more

Beam Therapeutics Announces Agreement for Eli Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31
Last Trade: 26.40 -2.35 -8.17

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics, Inc. (Verve), including Beam’s opt-in rights to co-develop and co-commercialize Verve’s base...Read more

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

October 31
Last Trade: 2.30 0.12 5.50

Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF) Financing proceeds of approximately $18 million from a private placement anticipated to fund completion of the ongoing Phase 1b clinical study of LTI-03 in IPF and for general corporate purposes Company to host conference call...Read more

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

October 31
Last Trade: 0.69 -0.07 -9.28

TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, announced today the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study of suramin's potential efficacy in treating acute kidney injury...Read more

United Therapeutics to Acquire Miromatrix Medical

October 30
Last Trade: 241.65 -0.42 -0.17

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn. / Oct 30, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a biotechnology...Read more

WELL Health Technologies Cycura Announces Two Tuck-In Acquisitions to Enhance Patient Data Protection and Appoints New Management

October 26
Last Trade: 3.95 0.14 3.67

WELL's Cybersecurity Business Unit, Cycura, has acquired Seekintoo, a provider of Cybersecurity Operations Center services, ensuring enterprise clients receive 24/7 vigilant threat protection through managed detection. Cycura has also acquired Proack, a premier provider of offensive security assessments, including high quality penetration testing, red teaming, social engineering, and infrastructure testing. WELL is pleased to announce...Read more

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology

October 24
Last Trade: 0.85 -0.0023 -0.27

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction anticipated to close in the first half of 2024 CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company...Read more

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 23
Last Trade: 9.83 0.08 0.82

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitis Roche will also obtain an option to enter into a global collaboration with Pfizer on a...Read more

AMN Healthcare to Acquire MSDR

October 23
Last Trade: 68.69 -0.11 -0.16

DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced a definitive agreement to acquire MSDR for a purchase price of $300 million. MSDR consists of two healthcare staffing companies that specialize in locum tenens and advanced practices, Medical Search International (MSI) and DRW Healthcare Staffing...Read more

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

October 23
Last Trade: 1.27 -0.05 -3.79

Expands Xtant’s Manufacturing Capabilities and Capacity to Drive Growth BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine. Under the terms of...Read more

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

October 23
Last Trade: 1.43 -0.06 -4.03

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine NAYA will seek to scale up profitable revenues in the fertility segment, enter into revenue-generating pharma partnerships for its therapeutic programs, and strategically develop and acquire synergistic technologies and...Read more

Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics

October 17
Last Trade: 489.77 -4.33 -0.88

Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportunities WALTHAM, Mass. & UPPSALA, Sweden / Oct 17, 2023 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving...Read more

Henry Schein Completes Acquisition of a Majority Interest in Shield Healthcare

October 17
Last Trade: 71.91 0.37 0.52

MELVILLE, N.Y. / Oct 17, 2023 / Business Wire / Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of Shield Healthcare, Inc., a leading supplier of homecare medical products delivered directly to patients in their homes. Henry Schein announced the agreement to acquire Shield Healthcare on August 3,...Read more

Small Pharma Obtains Final Order Approving Arrangement

October 17
Last Trade: 0.41 -0.001 -0.24

LONDON & TORONTO / Oct 17, 2023 / Business Wire / Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options,...Read more

OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers

October 12
Last Trade: 9.82 0.01 0.10

Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated revenue run rate will increase to nearly $100 million and the acquisition is expected to be immediately accretive to earnings. Third quarter 2023 headline numbers to come in ahead of consensus with revenue for OptimizeRx standalone expected...Read more

Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction

October 11
Last Trade: 3.68 0.01 0.27

BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding...Read more

Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals And Expands Pipeline

October 11
Last Trade: 31.00 -0.05 -0.16

New product in development diversifies portfolio to drive long-term growth  Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc....Read more

Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders

CHICAGO, IL / ACCESSWIRE / October 11, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a purchase agreement to acquire...Read more

Cigna: Evernorth Acquires Bright.md Technology Platform, Enhances MDLIVE's Virtual Care Experience for Patients and Clinicians

October 10
Last Trade: 258.80 0.86 0.33

Acquisition will add asynchronous care, triage, and navigation capabilities to Evernorth's MDLIVE virtual care platform for a more convenient, on-demand experience for patients and clinicians beginning in 2024 MDLIVE virtual primary care expands chronic condition care management to include health coaching beginning immediately BLOOMFIELD, Conn., Oct. 10, 2023 /PRNewswire/ -- Evernorth Health Services, the pharmacy, care, and...Read more

Teleflex Completes Acquisition of Palette Life Sciences

October 10
Last Trade: 231.08 -1.50 -0.64

WAYNE, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Palette Life Sciences AB. The acquisition adds Barrigel®, a biodegradable sculptable rectal spacer, to Teleflex’s Interventional Urology portfolio. Barrigel® is a Non-Animal Stabilized Hyaluronic Acid (NASHA) spacer designed to...Read more

Haemonetics Announces Definitive Agreement to Acquire OpSens

October 10
Last Trade: 84.84 1.58 1.90

Expands Haemonetics' Hospital portfolio with innovative fiber optic sensor technology for interventional cardiology Significant commercial synergies with Haemonetics' existing Vascular Closure portfolio Accelerates Haemonetics' transformational growth BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better...Read more

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

October 8
Last Trade: 50.31 0.15 0.30

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in...Read more

Amgen Completes Acquisition of Horizon Therapeutics

October 6
Last Trade: 269.12 -2.19 -0.81

Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion. "Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin...Read more

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

October 5
Last Trade: 149.28 1.31 0.89

Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease Activation of PINK1 remediates mitochondrial damage and restores mitochondrial function NORTH CHICAGO, Ill., Oct. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a...Read more

Kyowa Kirin to Acquire Orchard Therapeutics

October 5
Last Trade: 16.27 -0.01 -0.06

Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel) Acquisition price of $16.00 per ADS in cash plus an...Read more

Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech, Accelerating Timeline to Gain Control of Manufacturing and Research & Development

October 5
Last Trade: 0.17 0.0068 4.17

ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic devices for companion animals, today announced the acquisition of Qorvo Biotechnologies LLC (QBT), creators of the OmniaTM and TRUFORMA® point of care diagnostic platforms. Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo US, Inc., focused on the...Read more

EUDA Health Enters into Letter of Intent for Proposed Merger with TheoremRx

October 5
Last Trade: 1.19 0.02 1.71

SINGAPORE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering enhanced outcomes through personalized healthcare, today announced that it has signed a letter of intent dated October 4, 2023, with respect to the proposed merger with...Read more

Labcorp And Baystate Health Announce Strategic Relationship For Diagnostic Laboratory Services

October 4
Last Trade: 216.60 -1.03 -0.47

Labcorp to acquire Baystate Health's outreach laboratory business and select operating assets Collaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts BURLINGTON, N.C., Oct. 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s...Read more

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

October 4
Last Trade: 2.24 -0.11 -4.68

Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling opportunities and complementary offerings Generates estimated $80 million of annual cost synergies by 2026 and enhanced combined path...Read more

Eli Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies

October 3
Last Trade: 598.05 9.78 1.66

INDIANAPOLIS, Oct. 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a...Read more

Bruker Completes Acquisition of PhenomeX

October 3
Last Trade: 67.97 -0.83 -1.21

BILLERICA, Mass. / Oct 03, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash. Bruker announced the agreement to acquire PhenomeX on August 17, 2023. PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights into cellular...Read more

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

October 3
Last Trade: 7.73 0.03 0.39

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026* Expected to submit three investigational new drug applications (INDs) within 18 months SEATTLE & EXTON, Pa. / Oct 03, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology...Read more

AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide you with an update on our recent news of signing a definitive agreement to combine with GEDiCube (GEDiCube Press Release) (Renovaro Press Release) and to share our vision for the promising future of our newly combined company if you, as...Read more

Bausch + Lomb Completes Acquisition of XIIDRA®

September 29
Last Trade: 15.66 0.32 2.09

Poised for Significant Growth in Prescription Dry Eye Segment VAUGHAN, Ontario / Sep 29, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease...Read more

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine

September 29
Last Trade: 3.49 0.13 3.87

The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery AI technology products projected to be in marketplace in 2024 Phase 1/2 human studies of pancreatic cancer and other solid tumors with poor longevity projected to begin second half of 2024 LOS ANGELES, Sept. 29, 2023...Read more

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26
Last Trade: 239.29 0.17 0.07

Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and...Read more

Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova

September 26
Last Trade: 159.27 -2.60 -1.61

Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Management portfolio, complements single-use bag offering WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a...Read more

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

September 26
Last Trade: 19.00 0.00 0.00

Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. market Transaction price represents an 82% premium to Intercept’s closing price on September 25, 2023 Alfasigma adds Ocaliva®, the only FDA approved second-line treatment for PBC, a progressive autoimmune disease affecting the liver, which generated revenue of $152 million in 1H 2023 Strengthens...Read more

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

September 26
Last Trade: 0.52 0.02 4.89

$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps’ leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year and subsequent minimum orders totaling over $45...Read more

Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

September 25
Last Trade: 840.14 -9.04 -1.06

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic...Read more

Abbott Laboratories Completes Acquisition of Bigfoot Biomedical

September 22
Last Trade: 104.51 0.46 0.44

ABBOTT PARK, Ill., Sept. 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott's presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology and furthering the company's efforts to develop connected...Read more

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen

PLANO, Texas / Sep 21, 2023 / Business Wire / Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition...Read more

Cyclo Therapeutics and Applied Molecular Transport Enter into a Definitive Merger Agreement

September 21
Last Trade: 1.30 -0.02 -1.52

Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission GAINESVILLE,...Read more

Boston Scientific Announces Agreement to Acquire Relievant Medsystems

September 19
Last Trade: 54.95 -0.08 -0.15

Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass., Sept. 19, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous...Read more

bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services

September 19
Last Trade: 1.41 -0.11 -7.24

Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity’s Board of Directors Conference Call at 4:30 p.m. Eastern time Today SAN ANTONIO, Texas / Sep 19, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, announces the...Read more

Scilex Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

September 13
Last Trade: 1.10 0.01 0.92

PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed...Read more

Lucy Scientific Discovery Expands its Reach in the Global Wellness Market with BlueSky Wellness Acquisition

September 13
Last Trade: 0.30 -0.03 -7.91

VANCOUVER, BC / ACCESSWIRE / September 12, 2023 / Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a publicly traded company focused on the development, sale, delivery, and manufacturing of psychotropic products, recently announced its acquisition of all High Times IP and brand assets - has just announced the acquisition of BlueSky Wellness Inc., along with the full BlueSky portfolio of brands adding psychotropic products to its catalog,...Read more

Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

September 13
Last Trade: 0.41 -0.03 -7.32

FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing acute and...Read more

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

September 12
Last Trade: 127.20 -1.48 -1.15

Resolution Bioscience’s blood-based diagnostic tests complement Exact Sciences’ Precision Oncology portfolio, providing a more complete cancer treatment solution for patients, healthcare professionals, and biopharma partners SANTA CLARA, Calif. & MADISON, Wis. / Sep 12, 2023 / Business Wire / Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests,...Read more

Lucy Scientific Discovery Announces Acquisition of BlueSky Wellness in All-Stock Transaction

September 12
Last Trade: 0.30 -0.03 -7.91

VANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (NASDAQ: LSDI), the leader in the psychotropic industry, which recently celebrated the acquisition of High Times' Intellectual Property, the most iconic brand in the cannabis industry, is thrilled to announce an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands. This transaction expands Lucy’s footprint into the growing...Read more

Quipt Home Medical Announces Multi-State Acquisition Adding Approximately $9 Million in Annualized Revenues, and Anticipated $2 Million in Adjusted EBITDA Post Integration

September 11
Last Trade: 4.65 0.01 0.22

CINCINNATI, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is very pleased to announce that it has acquired a business with operations in Mississippi, Texas and Louisiana reporting unaudited annual revenues (12 months ending June 30, 2023) of approximately $9 million ‎with anticipated...Read more

Coherus BioSciences Completes Surface Oncology Acquisition

September 8
Last Trade: 2.22 -0.08 -3.48

Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment I-O combinations will potentially expand toripalimab opportunity into large indications with high unmet need REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously...Read more

Align Technology to Acquire Privately Held Direct 3D Printing Pioneer Cubicure to Support and Scale Company’s Strategic Innovation Roadmap

September 6
Last Trade: 221.23 4.62 2.13

LAS VEGAS & SAN JOSE, Calif. & TEMPE, Ariz. & VIENNA / Sep 06, 2023 / Business Wire / Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has entered into a definitive agreement to acquire privately held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing...Read more

NextGen Healthcare Enters into Definitive Agreement to Be Acquired by Thoma Bravo

September 6
Last Trade: 23.94 0.00 0.00

NextGen Healthcare Shareholders to Receive $23.95 Per Share in Cash, a 46.4% Premium to Unaffected Stock Price Transaction to Accelerate NextGen Healthcare’s Growth and Innovation as the Trusted Advisor to Healthcare Providers REMOTE-FIRST COMPANY/NEW YORK / Sep 06, 2023 / Business Wire / NextGen Healthcare, Inc. (Nasdaq: NXGN) (“NextGen Healthcare” or the “Company”), a leading provider of innovative, cloud-based healthcare technology...Read more

Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes

September 5
Last Trade: 104.51 0.46 0.44

Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support Together, Abbott and Bigfoot will...Read more

Amgen and Horizon Therapeutics Resolve FTC Lawsuit, Clearing Path to Close Acquisition

September 1
Last Trade: 269.12 -2.19 -0.81

THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the...Read more

Globus Medical Completes Merger with NuVasive

September 1
Last Trade: 46.51 1.18 2.60

Creates leading global musculoskeletal company Robust portfolio well-positioned for long-term growth and continued innovation AUDUBON, Pa., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasive, Inc. The combined company will provide surgeons and patients with one of the most comprehensive...Read more

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

August 31
Last Trade: 5.08 -0.06 -1.17

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra’s revenues OLPRUVA™ commercial operations provide Zevra scale and cost...Read more

Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...